ESTEVE to acquire medicine to treat medullary thyroid cancer

"Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth2. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives", confirms José María Giménez-Arnau, Chief Scientific & Medical Officer of ESTEVE.  

BARCELONA, Spain, 30/06/2025 (informazione.news - comunicati stampa - salute e benessere)

 confirms José María Giménez-Arnau, Chief Scientific & Medical Officer of ESTEVE.  

In April 2024 , ESTEVE acquired a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology, as a step forward towards becoming a highly specialized company. This acquisition added three new medicines to its portfolio addressing endogenous Cushing's syndrome and Adrenocortical Carcinoma.   

Furthermore, last month, ESTEVE acquired a license for a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency .  Building on this, the company last month, the company secured an adjuvant therapy considered the standard of care for high-grade, resectable, non-metastatic osteosarcoma in patients between 2 and 30 years of age .

 concludes Jacob Tolstrup , Chief Commercial Officer of ESTEVE. 

[The completion of the transaction is subject to obtaining customary regulatory clearances]. 

 

ESTEVE (www.esteve.com) is a global pharmaceutical company with a clear purpose: to improve people's lives. Founded in 1929 and headquartered in Barcelona , ESTEVE has a strong international presence with pharmaceutical affiliates in Spain , Portugal , Italy , Germany , France , the UK, and the USA.  

ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing services (CMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain , Mexico , and China. 

ESTEVE's strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.  

 

Irene Simón, Head of Global External Communications & ESG, ESTEVE
Tel.+34 934 466 000 – isimon@esteve.com  

Gemma Mestre , External & Digital Communications Manager, ESTEVE
Tel.+34 934 466 000 – gmestre@esteve.com 

Logo - https://mma.prnewswire.com/media/2649909/ESTEVE_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/esteve-to-acquire-medicine-to-treat-medullary-thyroid-cancer-302493686.html